VIP
A nasal spray that finishes a mold-illness protocol: fog lifts, exercise comes back. Only works late in the sequence, so not a first move.
What it is
VIP is for the person who has done the hard part of a mold or biotoxin illness recovery, got out of the water-damaged building, cleared the nasal staph, worked the lab markers down, and is still foggy, flat and unable to exercise without crashing. It is the last step of the Shoemaker CIRS protocol, a four-times-a-day nasal spray, and in the right sequence it is where people get their lives back.
Who actually uses it: people with chronic inflammatory response syndrome (CIRS) from mold, water-damaged buildings or other biotoxins, who have been through the earlier steps and have the labs to show it. That is nearly the entire population, and it should be. Casual use as a general anti-inflammatory spray is where the disappointments come from. If your problem is a gut that flares or an immune system that catches everything, KPV or Thymosin Alpha-1 are the tools, not this.
What you will notice, and when: in the right sequence, the change is fast and distinctive. Within days to a couple of weeks: the brain fog thins, you can tolerate a short walk or light workout without the two-day crash, breathing feels easier, and the strange sensitivity to light, static and temperature eases. Over one to three months, people describe getting their executive function back and their energy stabilizing. Good at 90 days looks like not needing it any more, because the protocol's goal is to taper to zero, not to stay on. Started too early, it does little or makes you feel worse, which is why the protocol insists on the order.
How it is run: one spray of 50 mcg, alternating nostrils, four times a day, for 30 to 90 days, then tapered. People start at one spray once or twice a day for a few days to check blood pressure and how they feel, then build to four. Some go to two sprays (100 mcg) per dose if the first month is tolerated and incomplete. The spray is mixed so each 0.1 mL pump delivers 50 mcg; a 5 mg vial is 100 sprays, 25 days at four a day, and VIP is fragile in solution, so mix only what you will use in a couple of weeks. The mistakes: starting it before the earlier steps are done (the single most common), skipping the lipase check, and treating a blood-pressure dip as something to push through.
The evidence, once: VIP is a natural neuropeptide with well-studied anti-inflammatory and vasodilating effects, and a related drug (aviptadil) has been trialed for pulmonary hypertension, sarcoidosis and critical lung illness. The CIRS use rests on one clinician's protocol, Ritchie Shoemaker's, with his published case series and years of use in his and allied practices, not on independent randomized trials or a formal safety study. So: real biology, one school of practice, consistent real-world results in the right patients, and nothing that proves it for anyone else.
When it is not worth it: if you have not done a CIRS workup and the earlier steps, because out of sequence it is money and frustration; if you have low blood pressure or a heart condition, because VIP widens blood vessels and that is the main side effect; if you are looking for a general anti-inflammatory or 'immune' spray. Thymosin Alpha-1 is the general immune-restoring tool and Chonluten the gentle airway bioregulator; VIP is the specialist's last step and is best run with someone who knows the protocol and the labs.
What people use it for
Mold and biotoxin illness (CIRS)
Some evidenceShoemaker's published case series report that VIP, given after the earlier protocol steps, corrected inflammatory markers, restored exercise tolerance, and improved brain-volume measures on MRI in CIRS patients, with few problems reported in his practice. This is one clinician's protocol and case data, not an independent randomized trial. In the right patient, in sequence, the real-world results are consistent.
Lungs and blood pressure in the lungs
Early daysA pharmaceutical form of VIP (aviptadil) has been trialed for pulmonary arterial hypertension, sarcoidosis and severe COVID lung injury, with mixed results. It confirms the molecule's vasodilating and anti-inflammatory activity in people and shows why blood pressure is the side effect to watch. It is not a home use.
Inflammation and the immune system
Some evidenceIn animal and cell work, VIP lowers inflammatory cytokines, shifts immune cells toward a calmer profile, and has been studied in arthritis and inflammatory bowel models. That is the mechanism the CIRS protocol relies on. Using it as a general anti-inflammatory in people has not been studied, and there are better-suited tools for that.
Gut and hormones
Early daysVIP is a gut hormone first; it regulates secretion and motility, and in CIRS it is credited with restoring hormone balance and MSH-related signaling. These effects are documented in physiology but have not been measured as outcomes of nasal VIP in any controlled study.
How it works
- Used mainly for inflammation and some breathing issues
- Typically taken as a nasal spray
- A natural signaling molecule found throughout the body
- Best used carefully and usually within a larger plan
How people use it
Safety, in brief
Things people sometimes notice
- Lightheadedness or a drop in blood pressure in the first week, especially standing up fast; this is why you start at one spray a day
- Flushing or a warm face for a few minutes after a spray
- Nasal irritation, a runny nose or a brief metallic taste
The full picture — stop signs and who should talk to a doctor first — is on the dosing guide.
Sources
The labels and studies behind this page. Each link opens the original on PubMed, DailyMed or ClinicalTrials.gov.
- Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis
- Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial
- Inhalation of vasoactive intestinal peptide in pulmonary hypertension
- Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease